3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
12
Pancreatic Neoplasms
10
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Neoplasm Metastasis
4
Sarcoma
3
Neuroblastoma
3
Biliary Tract Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Solid Tumors
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Refractory Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pathologic Complete Response
1
PRETEXT I Hepatoblastoma
1
Ovarian Neoplasms
1
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled